Wednesday, August 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 28, 2026

Is Starbucks's Stock a Buy Ahead of Its Q3 Earnings Report Tomorrow?

View original at nasdaq.com
Is Starbucks's Stock a Buy Ahead of Its Q3 Earnings Report Tomorrow? Key Points The company had a fine second quarter, and investors will be hoping for a repeat…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Starbucks is a mature business with a huge footprint that has little room to grow, and its stock is priced for hot growth with a forward P/E of almost 35 that profitability gains are unlikely to match; even a beat on Q3 earnings would not change this negative view

    60% confidence
  • Full-year 2026 comparable sales guidance raised to at least 5% growth (from more than 3% previously), and adjusted EPS guidance raised to $2.25-$2.45 (from $2.15-$2.40 previously)

    60% confidence
  • Starbucks attributed its solid second-quarter performance to the Back to Starbucks initiative

    60% confidence
  • Analysts collectively expect Starbucks to post just over $9.1 billion in revenue and $0.65 per share in net income for fiscal Q3 2026 — nearly 4% below the prior-year revenue figure but a 30% improvement in EPS year over year

    60% confidence

Data points we hold from this source

Starbucks Corporation · forward pe35 ratio
Starbucks Corporation · stock price23 percent_ytd_change
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com